WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006083645) FORMULATIONS AND DOSING REGIMEN FOR PPAR-ALPHA MODULATORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/083645    International Application No.:    PCT/US2006/002606
Publication Date: 10.08.2006 International Filing Date: 25.01.2006
Chapter 2 Demand Filed:    28.11.2006    
IPC:
A61K 31/4196 (2006.01), A61P 3/06 (2006.01), A61P 3/10 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US) (For All Designated States Except US).
ABU-RADDAD, Eyas, Jamal [JO/US]; (US) (For US Only).
DERBY, Michael, Arthur [US/US]; (US) (For US Only).
HARRIS, Cynthia, Joyce [US/US]; (US) (For US Only).
HOWEY, Daniel, Charles [US/US]; (US) (For US Only).
MICHAEL, Laura, Frey [US/US]; (US) (For US Only)
Inventors: ABU-RADDAD, Eyas, Jamal; (US).
DERBY, Michael, Arthur; (US).
HARRIS, Cynthia, Joyce; (US).
HOWEY, Daniel, Charles; (US).
MICHAEL, Laura, Frey; (US)
Agent: VORNDRAN-JONES, MaCharri; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US)
Priority Data:
60/647,903 28.01.2005 US
Title (EN) FORMULATIONS AND DOSING REGIMEN FOR PPAR-ALPHA MODULATORS
(FR) FORMULATIONS ET REGIMES DE DOSAGE POUR MODULATEURS DE PPAR-ALPHA
Abstract: front page image
(EN)The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihydro-l-[(4-methylphenyl)methyl]-5-oxo- lH-l,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- comprising 75 µg or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-l-[(4-methylphenyl)methyl]-5-oxo-lH-l,2,4-triazol-3- yl]propyl]phenoxy]-2-methyl- per dosage unit.
(FR)Régimes de dosage pour agonistes de PPAR-alpha et compositions correspondantes. Selon une variante, on décrit une formulation orale solide d'acide propanoïque, 2-[4-[3-[2,5-dihydro-l-[(4-méthylphényl)méthyl]-5-oxo- lH-l,2,4-triazol-3-yl]propyl]phénoxy]-2-méthyl- comprenant 75 µg, ou moins, d'acide propanoïque, 2-[4-[3-[2,5-dihydro-l-[(4-méthylphényl)méthyl]-5-oxo-lH-l,2,4-triazol-3- yl]propyl]phénoxy]-2-méthyl- par unité de dosage.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)